NVCT Nuvectis Pharma Inc

Price (delayed)

$21.07

Market cap

$686.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.31

Enterprise value

$664.33M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 1

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is ...

Highlights
The equity has contracted by 46% YoY and by 36% from the previous quarter
NVCT's quick ratio is down by 37% year-on-year and by 26% since the previous quarter

Key stats

What are the main financial stats of NVCT

NVCT stock price

How has the Nuvectis Pharma stock price performed over time
Intraday
-8.39%
1 week
-3.66%
1 month
-10.57%
1 year
251.17%
YTD
179.07%
QTD
14.57%

Financial performance

How have Nuvectis Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.87M
Net income
-$27.85M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 26% year-on-year and by 2.1% since the previous quarter
The net income has contracted by 26% YoY and by 2.5% from the previous quarter

Price vs fundamentals

How does NVCT's price correlate with its fundamentals

Growth

What is Nuvectis Pharma's growth rate over time

Valuation

What is Nuvectis Pharma stock price valuation
P/E
N/A
P/B
61.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NVCT's EPS is down by 12% year-on-year
The equity has contracted by 46% YoY and by 36% from the previous quarter

Efficiency

How efficient is Nuvectis Pharma business performance
The ROE has contracted by 22% YoY and by 14% from the previous quarter
The ROA has decreased by 11% YoY and by 6% QoQ

Dividends

What is NVCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCT.

Financial health

How did Nuvectis Pharma financials performed over time
Nuvectis Pharma's total assets is 68% more than its total liabilities
Nuvectis Pharma's current ratio has decreased by 37% YoY and by 26% from the previous quarter
NVCT's quick ratio is down by 37% year-on-year and by 26% since the previous quarter
NVCT's debt is 100% lower than its equity
The equity has contracted by 46% YoY and by 36% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.